Anti-inflammatory Treatment for Inactive Takayasu Arteritis

Learn more about:
Related Clinical Trial
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis Comparison of Tofacitinib and Methotrexate in Takayasu’s Arteritis A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis A Pilot Study in Severe Patients With Takayasu Arteritis. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis The Registry Study of Takayasu Arteritis in East China Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases A Registry Study on Biomarkers of Takayasu’s Arteritis (ARSBTA) Infliximab Biosimilar in Takayasu’s Arteritis Exercise in Juvenile Takayasu Disease Pulmonary Artery Involvement in Takayasu’s Arteritis Anti-inflammatory Treatment for Inactive Takayasu Arteritis Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Aerobic Capacity and Strength Exercise in Takayasu’s Arteritis Use of MRI and PET for Assessing Disease Activity in Takayasu’s Arteritis Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu’s Arteritis Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis Registration Study of Takayasu’s Arteritis in China Determining Disease Activity Biomarkers in Individuals With Takayasu’s Arteritis Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging China Takayasu Arteritis Registry (CTA Registry) Takayasu Arteritis Clinical Trial in China

Brief Title

Anti-inflammatory Treatment for Inactive Takayasu Arteritis

Official Title

Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment?

Brief Summary

      Currently, the traditional disease activity of Takayasu arteritis is mainly based on National
      Institutes of Health criteria and the inactive cases don't need anti-inflammatory treatment.
      However, pathologic findings showed that there was still inflammatory activity in the
      affected vessels, and the follow-up data also found significant lesion progression in some
      inactive cases. Sixty inactive Takayasu arteritis patients will be recruited to determine
      whether these individuals are active by screening new inflammatory markers in this study. New
      inflammatory markers included tumor necrosis
      factor,interleukin-2,interleukin-6,interleukin-8,interleukin-10,high-sensitivity C-reactive
      protein, and 18f-FDG positron emission tomograph. According to new inflammatory markers,
      sixty patients will be divided into two categories: inactive patients (n=20) and active
      patients (n=40). And then, Forty active patients diagnosed by new inflammatory markers will
      be randomly assigned to either anti-inflammatory therapy group or control group. The changes
      of inflammatory activity and lesion progression will be observed during one-year follow up in
      all 60 patients.

Study Phase

Phase 2/Phase 3

Study Type


Primary Outcome

Lesion progression

Secondary Outcome

 Lesion progression


Takayasu Arteritis


Prednisone, cyclophosphamide

Study Arms / Comparison Groups

 Anti-inflammatory treatment group
Description:  Prednisone and/or cyclophosphamide


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

June 1, 2018

Completion Date

May 31, 2021

Primary Completion Date

May 31, 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Takayasu arteritis diagnosed by the American College of Rheumatology 1990 criteria;

          2. Inactive Takayasu arteritis according to National Institutes of Health criteria;

          3. Age ≥ 14 and ≤ 40 years old at the time of informed consent;

          4. Patients or guardian agree to participate in the study.

        Exclusion Criteria:

          1. Active Takayasu arteritis according to National Institutes of Health criteria;

          2. Poor compliance, intolerance to or poor response to hormone therapy;

          3. Allergy to contrast agent;

          4. Renal insufficiency (serum creatinine >133μmol/L), cardiac insufficiency (NYHA
             functional class III and IV) or abnormal liver function (Alanine transaminase >1.5
             times upper limit of normal)




10 Years - 40 Years

Accepts Healthy Volunteers



Xiongjing Jiang, MD, 86-1088322385, [email protected]

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Study Sponsor

Xiongjing Jiang, MD, Principal Investigator, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Verification Date

June 2018